Menu Search
Equities

GemPharmatech Co Ltd

688046:SHH

GemPharmatech Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)11.11
  • Today's Change-0.12 / -1.07%
  • Shares traded1.63m
  • 1 Year change-36.22%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy2
Outperform5
Hold0
Sell0
Strong Sell0

Share price forecast in CNY

The 2 analysts offering 12 month price targets for GemPharmatech Co Ltd have a median target of 18.06, with a high estimate of 19.50 and a low estimate of 16.63. The median estimate represents a 62.56% increase from the last price of 11.11.
High75.5%19.50
Med62.6%18.06
Low49.7%16.63

Dividends

In 2023, GemPharmatech Co Ltd reported a dividend of 0.16 CNY, which represents a significant increase over last year. The 4 analysts covering the company expect dividends of 0.02 CNY for the upcoming fiscal year, a decrease of 88.75%.
Div growth (TTM)290.24%
More ▼

Earnings history & estimates in CNY

GemPharmatech Co Ltd reported annual 2023 earnings of 0.39 per share on Feb 23, 2024.
Average growth rate-7.14%
More ▼

Revenue history & estimates in CNY

GemPharmatech Co Ltd had revenues for the full year 2023 of 622.19m. This was 20.45% above the prior year's results.
Average growth rate+20.45%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.